<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066868</url>
  </required_header>
  <id_info>
    <org_study_id>1020/2019</org_study_id>
    <nct_id>NCT04066868</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-Rater Reliability of Common Terminology Criteria for Adverse Event Ratings</brief_title>
  <official_title>Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-Rater Reliability of Common Terminology Criteria for Adverse Event Ratings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bezirkskrankenhaus Kufstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università di Cagliari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansai Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open randomized trial investigates, if clinicians complete CTCAE ratings differently
      when receiving patients' patient-reported outcome (PRO) data prior to their CTCAE completion.
      The primary objective is to demonstrate superior inter-rater reliability of CTCAE ratings
      from physicians relying on EORTC PRO data as additional data source over traditional CTCAE
      ratings not including PRO information.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In oncology, detection and tracking of adverse events (AEs) are a top priority in both
      clinical trials and routine care. The classification of AEs mostly relies on the Common
      Toxicity Terminology for Adverse Events (CTCAE) developed by the US-American National
      Institutes of Health and the National Cancer Institute.

      It is known, however, that the assessment of AEs can greatly vary depending on whether they
      are assessed by patients or by clinicians.

      Procedure: The patients (any oncological diagnosis, day clinic or inpatient for treatment
      with chemotherapy or immunotherapy; open 1:1 randomized) fill out an EORTC quality of life
      questionnaire electronically (C30 + further questions). These PRO data are immediately
      available for the clinicians. Independently of each other, two different clinicians conduct a
      medical consultation with the patient and electronically a CTCAE rating. For the intervention
      Group, clinicians see the PRO values directly next to the input options for the CTCAE rating.
      For the control Group, clinicians see the input options for the CTCAE rating. The similarity
      of the assessments is checked using intra-class correlation.

      The combined use of PROs and CTCAE data makes particular sense for AEs/aspects that are
      directly experienced by the patient (fatigue, pain, cognitive problems, emotional
      functioning, ...) and can only be adequately recorded by the clinician through communication
      with the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC Quality of Life Questionnaire C30 and additional questions from the EORTC Item Library</measure>
    <time_frame>single assessment of quality of life before the medical consultation</time_frame>
    <description>patient-reported quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTCAE V4.0</measure>
    <time_frame>single assessment during the medical consultation with physician 1 on the same day of PRO assessment</time_frame>
    <description>physician 1 rates patient symptoms (17 CTCAE domains matching the EORTC C30 and additional questions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CTCAE V4.0</measure>
    <time_frame>single assessment during the medical consultation with physician 2 on the same day of PRO assessment</time_frame>
    <description>physician 2 rates patient symptoms (17 CTCAE domains matching the EORTC C30 and additional questions)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1024</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>PRO active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO not active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient-reported outcomes assessment</intervention_name>
    <description>Patient-reported outcomes are electronically assessed using EORTC QOL measures</description>
    <arm_group_label>PRO active</arm_group_label>
    <arm_group_label>PRO not active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CTCAE rating</intervention_name>
    <description>CTCAE Ratings are conducted by clinicians</description>
    <arm_group_label>PRO active</arm_group_label>
    <arm_group_label>PRO not active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRO data is displayed</intervention_name>
    <description>PRO data is displayed right next to the CTCAE rating</description>
    <arm_group_label>PRO active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any Cancer diagnosis

          -  current treatment with chemotherapy or immunotherapy

          -  symptom burden equal or greater score 3 of the screening question &quot;On a scale of 0 to
             10, to what degree did you experience physical or emotional symptoms/problems during
             the last week?&quot;

          -  ability to understand the questions linguistically and cognitively

          -  written informed consent

        Exclusion Criterion:

          -  psychiatric diagnosis or mental health problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernhard Holzner, Prof. PhD</last_name>
    <phone>+43(0)50 504 24253</phone>
    <email>berhard.holzner@tirol-kliniken.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>August Zabernigg, MD</last_name>
      <email>interne@bkh-kufstein.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patient-reported outcomes (PRO)</keyword>
  <keyword>common terminology criteria for adverse events (CTCAE)</keyword>
  <keyword>quality of life</keyword>
  <keyword>electronic data assessment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

